PuSH - Publication Server of Helmholtz Zentrum München: Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Rose, J.* ; Emery, V.C.* ; Kumar, D.* ; Asberg, A.* ; Hartmann, A.* ; Jardine, A.G.* ; Bignamini, A.A.* ; Humar, A.* ; Neumann, A.U.

Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection.

PLoS Pathog. 13:e1006299 (2017)

Publ. Version/Full Text

Research data

DOI

PMC

	Open Access Gold

Abstract
Metrics
Extra information

Human cytomegalovirus (CMV) infection is a substantial cause of morbidity and mortality in immunocompromised hosts and globally is one of the most important congenital infections. The nucleoside analogue ganciclovir (GCV), which requires initial phosphorylation by the viral UL97 kinase, is the mainstay for treatment. To date, CMV decay kinetics during GCV therapy have not been extensively investigated and its clinical implications not fully appreciated. We measured CMV DNA levels in the blood of 92 solid organ transplant recipients with CMV disease over the initial 21 days of ganciclovir therapy and identified four distinct decay patterns, including a new pattern exhibiting a transient viral rebound (Hump) following initial decline. Since current viral dynamics models were unable to account for this Hump profile, we developed a novel multi-level model, which includes the intracellular role of UL97 in the continued activation of ganciclovir, that successfully described all the decline patterns observed. Fitting the data allowed us to estimate ganciclovir effectiveness in vivo (mean 92%), infected cell half-life (mean 0.7 days), and other viral dynamics parameters that determine which of the four kinetic patterns will ensue. An important clinical implication of our results is that the virological efficacy of GCV operates over a broad dose range. The model also raises the possibility that GCV can drive replication to a new lower steady state but ultimately cannot fully eradicate it. This model is likely to be generalizable to other anti-CMV nucleoside analogs that require activation by viral enzymes such as UL97 or its homologues.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords Organ-transplant Recipients; Stem-cell Transplantation; Hepatitis-c; Preemptive Therapy; In-vivo; Antiviral Chemotherapy; Replication Kinetics; Controlled-trial; Mixed Infection; Viral Dynamics

ISSN (print) / ISBN 1553-7366

e-ISSN 1553-7374

Journal PLoS Pathogens

Quellenangaben Volume: 13, Issue: 4, Article Number: e1006299

Publisher Public Library of Science (PLoS)

Publishing Place San Francisco

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Institute of Environmental Medicine (IEM)